
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6856519/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology, 2001, 33, 1394-1403.	3.6	1,931
2	Incubation period of AIDS in San Francisco. Nature, 1989, 338, 251-253.	13.7	360
3	CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathogens, 2016, 12, e1005761.	2.1	350
4	Comparison of Custom and Prefabricated Orthoses in the Initial Treatment of Proximal Plantar Fasciitis. Foot and Ankle International, 1999, 20, 214-221.	1.1	323
5	Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size. Journal of Infectious Diseases, 2013, 208, 1202-1211.	1.9	285
6	Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV,the, 2015, 2, e520-e529.	2.1	213
7	RISK FACTORS FOR AIDS AND HIV SEROPOSITIVITY IN HOMOSEXUAL MEN. American Journal of Epidemiology, 1987, 125, 1035-1047.	1.6	187
8	Interferon-α therapy for hepatitis c virus infection after liver transplantation. Hepatology, 1994, 20, 773-779.	3.6	177
9	Increase in 2–Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial. Journal of Infectious Diseases, 2013, 208, 1436-1442.	1.9	151
10	Peripheral Vascular Disease Risk Factors among Patients Undergoing Hemodialysis. Journal of the American Society of Nephrology: JASN, 2002, 13, 497-503.	3.0	150
11	Differential decay of intact and defective proviral DNA in HIV-1–infected individuals on suppressive antiretroviral therapy. JCI Insight, 2020, 5, .	2.3	140
12	Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease. Hepatology, 1994, 20, 105-110.	3.6	139
13	Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. Journal of Infectious Diseases, 2015, 212, 596-607.	1.9	138
14	Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to patient survival. Hepatology, 1994, 20, 1152-1155.	3.6	136
15	Current sample size conventions: Flaws, harms, and alternatives. BMC Medicine, 2010, 8, 17.	2.3	136
16	Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). PLoS ONE, 2014, 9, e83736.	1.1	125
17	Effects of a mindfulness-based intervention on mindful eating, sweets consumption, and fasting glucose levels in obese adults: data from the SHINE randomized controlled trial. Journal of Behavioral Medicine, 2016, 39, 201-213.	1.1	124
18	Breaking Free of Sample Size Dogma to Perform Innovative Translational Research. Science Translational Medicine, 2011, 03, 87ps24.	5.8	122

#	Article	IF	CITATIONS
19	Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7795-E7804.	3.3	121
20	Peer review of statistics in medical research: the other problem. BMJ: British Medical Journal, 2002, 324, 1271-1273.	2.4	119
21	Effects of a mindfulnessâ€based weight loss intervention in adults with obesity: A randomized clinical trial. Obesity, 2016, 24, 794-804.	1.5	113
22	Ethics and Sample Size. American Journal of Epidemiology, 2005, 161, 105-110.	1.6	102
23	Estimating the Incubation Period of AIDS by Comparing Population Infection and Diagnosis Patterns. Journal of the American Statistical Association, 1990, 85, 1002-1008.	1.8	101
24	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus–Infected Individuals Receiving Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 911-919.	1.9	95
25	RAPID antiretroviral therapy. Aids, 2019, 33, 825-832.	1.0	83
26	Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. Clinical Infectious Diseases, 2018, 66, 213-219.	2.9	82
27	Simple, Defensible Sample Sizes Based on Cost Efficiency. Biometrics, 2008, 64, 577-585.	0.8	74
28	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. Journal of Infectious Diseases, 2019, 219, 1084-1094.	1.9	73
29	Tired telomeres: Poor global sleep quality, perceived stress, and telomere length in immune cell subsets in obese men and women. Brain, Behavior, and Immunity, 2015, 47, 155-162.	2.0	62
30	Biliary complications of reduced-organ liver transplantation. Liver Transplantation, 1998, 4, 343-349.	1.9	60
31	A Single-Nucleotide Polymorphism in CYP2B6 Leads to >3-Fold Increases in Efavirenz Concentrations in Plasma and Hair Among HIV-Infected Women. Journal of Infectious Diseases, 2012, 206, 1453-1461.	1.9	59
32	Changes in Bone Resorption During the Menstrual Cycle. Journal of Bone and Mineral Research, 1999, 14, 609-615.	3.1	58
33	Additive Isotonic Models. Journal of the American Statistical Association, 1989, 84, 289-294.	1.8	56
34	Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS Research and Human Retroviruses, 2017, 33, 778-783.	0.5	52
35	Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort. Neurology, 2014, 83, 1705-1711.	1.5	51
36	Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 72-77.	0.9	50

#	Article	IF	CITATIONS
37	Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants. Clinical Transplantation, 2000, 14, 167-173.	0.8	49
38	Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. Aids, 2017, 31, 2245-2251.	1.0	47
39	Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients. PLoS ONE, 2015, 10, e0129100.	1.1	43
40	Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence. EClinicalMedicine, 2018, 2-3, 22-28.	3.2	42
41	Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology, 2018, 90, e254-e260.	1.5	41
42	Recipient clinical risk factors predominate in possible transfusionâ€related acute lung injury. Transfusion, 2015, 55, 947-952.	0.8	40
43	Human Immunodeficiency Virus (HIV)–Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy. Journal of Infectious Diseases, 2020, 221, 744-755.	1.9	39
44	Memory CD4 + T-Cells Expressing HLA-DR Contribute to HIV Persistence During Prolonged Antiretroviral Therapy. Frontiers in Microbiology, 2019, 10, 2214.	1.5	38
45	Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings. Aids, 2020, 34, 255-260.	1.0	38
46	Outcomes after ileoanal pouch surgery in frail and older adults. Journal of Surgical Research, 2015, 198, 327-333.	0.8	37
47	Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients. Liver Transplantation, 1999, 5, 136-143.	1.9	35
48	Race and Hepatitis C Care Continuum in an Underserved Birth Cohort. Journal of General Internal Medicine, 2019, 34, 2005-2013.	1.3	35
49	Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children. AIDS Research and Human Retroviruses, 2015, 31, 1009-1014.	0.5	32
50	A randomized, controlled trial of mindfulness-based stress reduction in HIV infection. Brain, Behavior, and Immunity, 2018, 73, 331-339.	2.0	32
51	Survival trees with time-dependent covariates: Application to estimating changes in the incubation period of AIDS. Lifetime Data Analysis, 1995, 1, 35-47.	0.4	30
52	Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIVâ€1 Transcription in a Phase IIb Trial. Clinical Pharmacology and Therapeutics, 2019, 105, 692-702.	2.3	29
53	Strategies to Improve Follow-up After Positive Fecal Immunochemical Tests in a Community-Based Setting: A Mixed-Methods Study. Clinical and Translational Gastroenterology, 2019, 10, e00010.	1.3	27
54	Lifeâ€Space Assessment Predicts Hospital Readmission in Homeâ€Limited Adults. Journal of the American Geriatrics Society, 2017, 65, 1004-1011.	1.3	25

#	Article	IF	CITATIONS
55	Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to patient survival. Hepatology, 1994, 20, 1152-1155.	3.6	25
56	Swiss medical centres vary significantly when it comes to outcomes ofÂneonates with a very low gestational age. Acta Paediatrica, International Journal of Paediatrics, 2015, 104, 872-879.	0.7	24
57	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. EBioMedicine, 2021, 65, 103241.	2.7	24
58	Estimating the Incubation Period of AIDS by Comparing Population Infection and Diagnosis Patterns. , 0, .		23
59	Best Practices for Biostatistical Consultation and Collaboration in Academic Health Centers. American Statistician, 2016, 70, 187-194.	0.9	22
60	Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression. AIDS Research and Human Retroviruses, 2017, 33, 658-667.	0.5	22
61	Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size. PLoS Computational Biology, 2019, 15, e1006849.	1.5	22
62	Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial. Clinical Infectious Diseases, 2019, 68, 1044-1047.	2.9	22
63	Use of antimüllerian hormone to predict the menopausal transition in HIV-infected women. American Journal of Obstetrics and Gynecology, 2017, 216, 46.e1-46.e11.	0.7	21
64	Effect of a Patient-Centered Decision Support Tool on Rates of Trial of Labor After Previous Cesarean Delivery. JAMA - Journal of the American Medical Association, 2020, 323, 2151.	3.8	21
65	Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. BMC Infectious Diseases, 2007, 7, 145.	1.3	20
66	Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites. Journal of Virology, 2020, 94, .	1.5	20
67	Seasonal and other short-term influences on United States AIDS incidence. Statistics in Medicine, 1994, 13, 1921-1931.	0.8	18
68	Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. PLoS ONE, 2018, 13, e0190118.	1.1	18
69	Measuring Adherence to Antiretroviral Therapy via Hair Concentrations in India. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 202-206.	0.9	18
70	Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size. Journal of Infectious Diseases, 2021, 224, 1209-1218.	1.9	18
71	Food Insecurity Is Associated With Lower Levels of Antiretroviral Drug Concentrations in Hair Among a Cohort of Women Living With Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases, 2020, 71, 1517-1523.	2.9	17
72	Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis. PLoS ONE, 2016, 11, e0155887.	1.1	15

#	Article	IF	CITATIONS
73	Impact of a Mindfulness-Based Weight-Loss Intervention on Sleep Quality Among Adults with Obesity: Data from the SHINE Randomized Controlled Trial. Journal of Alternative and Complementary Medicine, 2017, 23, 188-195.	2.1	14
74	Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine. Aids, 2018, 32, 2189-2194.	1.0	14
75	Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e15029.	0.5	14
76	Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 202-208.	0.9	12
77	Generalized Additive Models with Interval-Censored Data and Time-Varying Covariates: Application to Human Immunodeficiency Virus Infection in Hemophiliacs. Biometrics, 2002, 58, 443-447.	0.8	11
78	Age and Variant Creutzfeldt-Jakob Disease. Emerging Infectious Diseases, 2003, 9, 1611-1612.	2.0	11
79	Progression of Biopsy-Measured Liver Fibrosis in Untreated Patients with Hepatitis C Infection: Non-Markov Multistate Model Analysis. PLoS ONE, 2011, 6, e20104.	1.1	11
80	Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2018, 32, 431-441.	0.7	11
81	Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women. Aids, 2019, 33, 1657-1662.	1.0	11
82	Effect of Present-on-Admission (POA) Reporting Accuracy on Hospital Performance Assessments Using Risk-Adjusted Mortality. Health Services Research, 2015, 50, 922-938.	1.0	10
83	The association of patient preferences and attitudes with trial of labor after cesarean. Journal of Perinatology, 2019, 39, 1340-1348.	0.9	10
84	Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy. Journal of Clinical Microbiology, 2020, 58, .	1.8	10
85	An LC-MS/MS-based method to analyze the anti-tuberculosis drug bedaquiline in hair. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1069-1070.	0.6	9
86	Simultaneous analysis of 11 medications for drug resistant TB in small hair samples to quantify adherence and exposure using a validated LC-MS/MS panel. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1125, 121729.	1.2	9
87	Women's Preferences Regarding the Processes and Outcomes of Trial of Labor After Cesarean and Elective Repeat Cesarean Delivery. Journal of Women's Health, 2019, 28, 1143-1152.	1.5	9
88	Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB. ERJ Open Research, 2019, 5, 00046-2019.	1.1	9
89	A multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs. International Journal of Tuberculosis and Lung Disease, 2016, 20, 991-992.	0.6	6
90	Statistical analysis of single-copy assays when some observations are zero. Journal of Virus Eradication, 2019, 5, 167-173.	0.3	5

#	Article	IF	CITATIONS
91	Statistical analysis of single-copy assays when some observations are zero. Journal of Virus Eradication, 2019, 5, 167-173.	0.3	5
92	Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Women. Clinical Infectious Diseases, 2017, 65, 1695-1702.	2.9	4
93	Uncertainty due to model choice in variant Creutzfeldt–Jakob disease projections. Statistics in Medicine, 2005, 24, 83-93.	0.8	3
94	Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1169, 122467.	1.2	3
95	Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting. BMC Infectious Diseases, 2021, 21, 99.	1.3	3
96	Moderate Alcohol Use and Insulin Action in Chronic Hepatitis C Infection. Digestive Diseases and Sciences, 2016, 61, 2417-2425.	1.1	2
97	Association of Pharmacogenetic Markers With Atazanavir Exposure in HIVâ€Infected Women. Clinical Pharmacology and Therapeutics, 2020, 107, 315-318.	2.3	2
98	Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	2
99	Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples. Journal of Visualized Experiments, 2020, , .	0.2	2
100	INCIDENCE OF HIV-RELATED DEATHS IN THE UNITED STATES: SEASONALITY AND TREND. Statistics in Medicine, 1997, 16, 645-652.	0.8	1
101	Increases in Mindful Eating Predict Reductions in Consumption of Sweets and Desserts: Data from the Supporting Health by Integrating Nutrition and Exercise (SHINE) Clinical Trial. Journal of Alternative and Complementary Medicine, 2014, 20, A17-A17.	2.1	1
102	A Genomeâ€Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair. Clinical Pharmacology and Therapeutics, 2018, 104, 949-956.	2.3	1
103	Impact of Moderate Alcohol Discontinuation on InsulinÂAction and Secretion in Latinos With and Without Hepatitis C. Alcoholism: Clinical and Experimental Research, 2018, 42, 492-499.	1.4	1
104	Association between Use of Methadone, Other Central Nervous System Depressants, andQTc Interval–Prolonging Medications and Risk of Mortality in a Large Cohort of Women Living with or at Risk for Human Immunodeficiency Virus Infection. Pharmacotherapy, 2019, 39, 899-911.	1.2	1
105	The Other Arbitrary Cutoff. American Statistician, 2019, 73, 413-414.	0.9	0
106	Disentangling the impact of alcohol use and hepatitis C on insulin action in Latino individuals. Alcoholism: Clinical and Experimental Research, 2022, 46, 87-99.	1.4	0